Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2026)
Inhibikase Therapeutics (IKT) posted quarterly EPS (Basic) of -$0.1 for Q1 2026, up 36.5% year-over-year from -$0.08 in Q1 2025, and up 77.59% quarter-over-quarter from -$0.46 in Q4 2025.
Inhibikase Therapeutics (IKT) EPS (Basic) (2020 - 2026) Analysis & Trends
Inhibikase Therapeutics (IKT) has reported EPS (Basic) for 7 consecutive years, with -$0.1 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) rose 36.5% year-over-year to -$0.1; the TTM figure through Mar 2026 stood at -$0.5 (down 16.55% YoY), while the FY2025 annual figure was -$0.85, up 66.2% from the prior year.
- EPS (Basic) improved to -$0.1 in Q1 2026 per IKT's latest filing, from -$0.46 in the prior quarter.
- Across five years, EPS (Basic) topped out at -$0.1 in Q1 2026 and bottomed at -$1.19 in Q2 2023.
- Historically, EPS (Basic) has averaged -$0.7 across 5 years, with a median of -$0.76 in 2024.
- Annual changes were most pronounced in 2023 — EPS (Basic) dropped 8.25% — and 2025, when it surged 82.64%.
- Inhibikase Therapeutics' EPS (Basic) stood at -$1.03 in 2022, then gained by 19.96% to -$0.83 in 2023, then jumped by 33.97% to -$0.55 in 2024, then grew by 15.24% to -$0.46 in 2025, then surged by 77.59% to -$0.1 in 2026.
- Business Quant data shows IKT's EPS (Basic) at -$0.1 in Q1 2026, -$0.46 in Q4 2025, and -$0.14 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 7.59 |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.06 |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.16 |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 0.00 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 0.18 |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.23 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.06 |
| 10 | Inhibikase Therapeutics | 420.72 Mn | 261.70 Mn | - | -0.12 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -0.12 |
| Mar 31, 2026 | -0.10 |
| Dec 31, 2025 | -0.46 |
| Sep 30, 2025 | -0.14 |
| Jun 30, 2025 | -0.12 |
| Mar 31, 2025 | -0.16 |
| Dec 31, 2024 | -0.55 |
| Sep 30, 2024 | -0.67 |
| Jun 30, 2024 | -0.70 |
| Mar 31, 2024 | -0.76 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.90 |
| Jun 30, 2023 | -1.19 |
| Mar 31, 2023 | -1.04 |
| Dec 31, 2022 | -1.03 |
| Sep 30, 2022 | -1.09 |
| Jun 30, 2022 | -1.10 |
| Mar 31, 2022 | -1.10 |
| Dec 31, 2021 | -1.66 |
| Sep 30, 2021 | -1.07 |